These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 1382154)

  • 1. ACE inhibitors and end-organ damage in cardiovascular disease: kidney and nervous system in hypertension. Proceedings of the Erasmus Medical Workshops.
    J Cardiovasc Pharmacol; 1992; 19 Suppl 6():S1-145. PubMed ID: 1382154
    [No Abstract]   [Full Text] [Related]  

  • 2. ACE inhibitors and end-organ damage in cardiovascular disease: vessel-wall damage and cardiac function in hypertension. Proceedings of the Erasmus Medical Workshops.
    J Cardiovasc Pharmacol; 1992; 19 Suppl 5():S1-139. PubMed ID: 1381783
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE; Julius S
    Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors: where do we stand now?
    Böhm M
    Am J Cardiol; 2007 Aug; 100(3A):38J-44J. PubMed ID: 17666197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Should all patients at high cardiovascular risk receive renin-angiotensin system blockers?
    Volpe M
    QJM; 2012 Jan; 105(1):11-27. PubMed ID: 22011630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What to treat? The structural basis for renal and vascular complications and hypertension, and the role of angiotensin converting enzyme inhibition. Symposium, 26th meeting of the European Association for the Study of Diabetes. Dublin, Ireland, 10 September 1991.
    J Hypertens Suppl; 1992 Apr; 10(1):S1-53. PubMed ID: 1619498
    [No Abstract]   [Full Text] [Related]  

  • 8. The impact of ACE inhibition on all-cause and cardiovascular mortality in contemporary hypertension trials: a review.
    Ferrari R; Boersma E
    Expert Rev Cardiovasc Ther; 2013 Jun; 11(6):705-17. PubMed ID: 23750680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RAS inhibition in hypertension.
    Ibrahim MM
    J Hum Hypertens; 2006 Feb; 20(2):101-8. PubMed ID: 16397519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishing a new option for target-organ protection: rationale for ARB plus ACE inhibitor combination therapy.
    Cohn JN; Goldman JM
    Am J Hypertens; 2008 Mar; 21(3):248-56. PubMed ID: 18219303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the Renin-Angiotensin-Aldosterone System and Its Pharmacological Inhibitors in Cardiovascular Diseases: Complex and Critical Issues.
    Borghi C; ; Rossi F;
    High Blood Press Cardiovasc Prev; 2015 Dec; 22(4):429-44. PubMed ID: 26403596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ACE inhibitors and survival of hemodialysis patients.
    Efrati S; Zaidenstein R; Dishy V; Beberashvili I; Sharist M; Averbukh Z; Golik A; Weissgarten J
    Am J Kidney Dis; 2002 Nov; 40(5):1023-9. PubMed ID: 12407648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A threat to cardiovascular risk patients. "Activated renin-angiotensin system promotes end organ damage" (interview by Waldtraud Paukstadt)].
    Schunkert H
    MMW Fortschr Med; 2004 Jun; 146(23):60. PubMed ID: 15373137
    [No Abstract]   [Full Text] [Related]  

  • 14. Antihypertensive therapy and blood lipids: ACE inhibitors.
    Agner E
    Scand J Clin Lab Invest Suppl; 1990; 199():55-9. PubMed ID: 2191418
    [No Abstract]   [Full Text] [Related]  

  • 15. [ACE-inhibitors in renal protection].
    Barna I
    Orv Hetil; 2006 Jun; 147(22):1019-23. PubMed ID: 16913091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly.
    Wing LM; Reid CM; Ryan P; Beilin LJ; Brown MA; Jennings GL; Johnston CI; McNeil JJ; Macdonald GJ; Marley JE; Morgan TO; West MJ;
    N Engl J Med; 2003 Feb; 348(7):583-92. PubMed ID: 12584366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers?
    Ruilope LM
    Acta Diabetol; 2005 Apr; 42 Suppl 1():S33-41. PubMed ID: 15868118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The future of renin inhibition].
    Uresin AY; Baran E
    Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():32-8. PubMed ID: 20019475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent changes in the landscape of combination RAS blockade.
    Epstein BJ; Smith SM; Choksi R
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Added organ protection at little cost. Double savings with ACE inhibitors].
    MMW Fortschr Med; 2003 Nov; 145(48):63. PubMed ID: 14725008
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.